International Journal of Pharmacology and Clinical Sciences,2023,12,1,14-16.
Registrations: Abrocitinib had been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (SA). Trade name (USA.); CIBINQO® Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (28.1.2023). General Information: Registered Company: By Pfizer company. Regulatory Status: R.X. Mechanism of Action: It is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Indication Approved (Labeled) indication Atopic dermatitis (Moderate to Severe), Refractory to other systemic drug products, including biologics, or when the use of such therapies is inadvisable. Read more..